药房

Search documents
达嘉维康:拟收购安徽达嘉维康健康大药房有限公司60.85%股权
news flash· 2025-07-11 11:48
达嘉维康(301126.SZ)公告称,公司拟以自有资金或自筹资金收购安徽达嘉维康健康大药房有限公司 60.85%的股权,交易价格为11,561.50万元。交易完成后,安徽达嘉维康将成为公司控股子公司,纳入 公司合并报表范围。此次交易构成关联交易,公司董事会已审议通过该议案,并授权公司董事长签署相 关合同文件。 ...
漱玉平民: 第四届监事会第五次会议决议公告
Zheng Quan Zhi Xing· 2025-07-09 11:13
证券代码:301017 证券简称:漱玉平民 公告编号:2025-062 漱玉平民大药房连锁股份有限公司(以下简称"公司")第四届监事会第五次会议于 以书面、电子邮件等方式向公司全体监事发出。本次会议由监事会主席孟鹏女士召集并主 持,会议应到监事 3 人,实到监事 3 人,董事会秘书以通讯方式列席了本次会议。本次会 议召开符合《中华人民共和国公司法》及《公司章程》等有关规定。 二、监事会会议审议情况 审议通过《关于使用部分闲置募集资金暂时补充流动资金的议案》 监事会认为:公司本次使用部分闲置募集资金暂时补充流动资金,有利于满足公司流 动资金需求,提高募集资金使用效率,降低财务成本,不影响募集资金投资项目的正常实 施,不存在变相改变募集资金投向和损害股东利益的情形,符合公司及全体股东的利益。因 此,监事会同意本次使用部分闲置募集资金暂时补充流动资金的事项。 表决结果:同意 3 票;反对 0 票;弃权 0 票。 债券代码:123172 债券简称:漱玉转债 漱玉平民大药房连锁股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、 误导性陈述或者重大遗漏。 一、监事会会议召开情况 三、备 ...
老百姓大药房连锁股份有限公司2024年年度权益分派实施公告
Shang Hai Zheng Quan Bao· 2025-07-07 19:15
Core Points - The company announced a cash dividend distribution of 0.08 yuan per share for the fiscal year 2024, approved at the shareholders' meeting on June 30, 2025 [2][4] - The total cash dividend to be distributed amounts to approximately 60.81 million yuan, based on a total share capital of 760,095,613 shares [4] - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [3] Distribution Plan - The cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited, with shareholders who have completed designated transactions able to receive their dividends on the payment date [5] - The distribution does not involve the issuance of bonus shares or capital increases [6] - Direct cash dividends will be issued to specific shareholders, including Lao Bai Xing Medical Group Co., Ltd., Zexing Investment Co., Ltd., and Chen Xiulan [9] Taxation Details - For individual shareholders and securities investment funds holding unrestricted circulating shares, no income tax will be withheld at the time of dividend distribution, with the actual cash dividend being 0.08 yuan per share [10] - Tax liabilities will be calculated based on the holding period of the shares, with different tax rates applicable: 20% for holdings of one month or less, 10% for holdings between one month and one year, and no tax for holdings over one year [10] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.072 yuan per share [11]
益丰大药房连锁股份有限公司关于可转债转股结果暨股份变动公告
Shang Hai Zheng Quan Bao· 2025-07-02 19:14
Summary of Key Points Core Viewpoint The announcements from Yifeng Pharmacy Chain Co., Ltd. detail the status of its convertible bonds and the management of idle raised funds through financial products, indicating a strategic approach to enhance financial efficiency and shareholder returns. Group 1: Convertible Bond Conversion Status - As of June 30, 2025, a total face value of 163,000 yuan of "Yifeng Convertible Bonds" has been converted into 4,950 shares of the company's A-shares, representing 0.0004% of the total shares before conversion [2][4]. - The remaining unconverted "Yifeng Convertible Bonds" have a face value of 1,797,269,000 yuan, accounting for 99.9909% of the total issuance [2][4]. - During the quarter from April 1, 2025, to June 30, 2025, 2,000 yuan of "Yifeng Convertible Bonds" were converted into 60 shares [2][4]. Group 2: Convertible Bond Issuance Overview - The company issued 17,974,320 convertible bonds with a total face value of 179,743.20 million yuan, approved by the China Securities Regulatory Commission on March 4, 2024 [3]. - The bonds were listed on the Shanghai Stock Exchange on March 27, 2024, and can be converted into shares starting from September 9, 2024 [3]. Group 3: Management of Idle Funds - The company redeemed structured deposits totaling 10,300.00 million yuan and plans to continue investing 11,400.00 million yuan in new financial products [6][8]. - The board approved the use of up to 30,000.00 million yuan of idle raised funds for financial investments, ensuring that it does not affect the normal operation of investment projects [6][10]. - The investment strategy aims to enhance the efficiency of idle funds and increase company returns without impacting daily operations [13].
老百姓: 2024年年度股东大会决议公告
Zheng Quan Zhi Xing· 2025-06-30 16:34
Meeting Details - The shareholders' meeting was held on June 30, 2025, at the company's conference room in Changsha, Hunan Province [1] - The meeting was attended by shareholders representing 50.8455% of the total shares [1] - Voting was conducted through a combination of on-site and online methods, and the meeting was presided over by Chairman Xie Zilong [1] Voting Results - All non-cumulative voting proposals were approved with high support, including: - Proposal 1: 99.9280% approval from A-shareholders [1] - Proposal 2: 99.9237% approval from A-shareholders [1] - Proposal 3: 99.9208% approval from A-shareholders [1] - Proposal 4: 99.9272% approval from A-shareholders [1] - The voting results indicate a strong consensus among shareholders for the proposed resolutions [2][3] Legal Compliance - The meeting's procedures were confirmed to comply with the Company Law and relevant regulations, ensuring the legality and validity of the meeting and voting results [4]
益丰药房: 益丰药房关于可转换公司债券跟踪评级结果的公告
Zheng Quan Zhi Xing· 2025-06-26 16:17
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 证券代码:603939 证券简称:益丰药房 公告编号:2025-060 债券代码:113682 转债简称:益丰转债 益丰大药房连锁股份有限公司 关于可转换公司债券跟踪评级结果的公告 前次评级展望为"稳定";评级机构为联合资信,评级时间为 2024 年 6 月 21 日。 联合资信在对公司经营状况、行业情况进行综合分析与评估的基础上,于 换公司债券 2025 年跟踪评级报告》,本次公司主体信用评级结果为"AA","益 丰转债"评级结果为"AA",评级展望维持"稳定"。本次评级结果较前次没有 变化。 本次信用评级报告详见上海证券交易所网站(www.sse.com.cn)。 特此公告。 益丰大药房连锁股份有限公司 ? 前次转债评级:AA,主体评级:AA,评级展望:稳定 ? 本次转债评级:AA,主体评级:AA,评级展望:稳定 ? 本次评级结果较上次无变化。 根据《公司债券发行与交易管理办法》《上海证券交易所股票交易规则》和 《上市公司证券发行管理办法》等有关规定,益丰大药 ...
特朗普考虑“影子联储主席”,美元和美债收益率走低,美股三大指数走高,小米ADR涨超10%
Hua Er Jie Jian Wen· 2025-06-26 15:33
26日周四,尽管美国经济数据好坏参半,美股三大指数依然走高,标普500指数逼近历史新高,AI乐观 预期推动科技股继续领涨。同时,市场正在加码押注年内将有两次降息,首次降息时间可能在9月,7月 降息的概率仍维持在20%左右。降息预期增强,推动美股、美债走高,美元指数跌至两年新低。欧股回 吐涨幅,油价两日连涨,现货黄金跌幅扩大,加密货币冲高回落。 美股盘前公布数据显示,坏的方面,美国一季度GDP终值下修至萎缩0.5%;5月商品贸易逆差意外扩 大,出口创下疫情以来最大降幅;美国续请失业救济人数升至三年半最高。好的方面,美国上周首申失 业救济人数小幅下滑。数据略显疲软,但市场认为这反而更可能促使美联储降息。 另外,即使鲍威尔还没离职,报道称特朗普可能最早在今年9月宣布鲍威尔的接替人选,通过鸽派的"影 子美联储主席"来影响市场,增强美联储提前降息预期。美联储官员依旧有分歧,周四旧金山联储主席 戴利表示,目前越来越多的证据表明,关税不太可能引发持续性通胀上升。但里士满联储主席巴金则 说,关税很可能会推高物价,美联储应继续观望。 以下为核心资产走势: 美股三大指数走高,道指盘中涨约0.6%,标普500指数涨超0.4%,纳指 ...
Walgreens Q3 Earnings Top Estimates, Stock Up, Gross Margin Declines
ZACKS· 2025-06-26 14:06
Key Takeaways WBA posted Q3 adjusted EPS of $0.38, beating estimates but falling nearly 40% year over year. WBA reported $38.99B in Q3 sales, up 7.2% year over year and ahead of the consensus by 6.5%. The gross margin fell 108 bps to 16.7%. WBA withdrew fiscal 2025 guidance amid the pending Sycamore deal.Walgreens Boots Alliance, Inc. (WBA) delivered adjusted earnings per share (EPS) of 38 cents in the third quarter of fiscal 2025, down 39.7% from the year-ago quarter’s figure (down 39.6% at the constant ...
漱玉平民: 关于持股5%以上股东、董事、高级管理人员权益变动比例触及1%整数倍的提示性公告
Zheng Quan Zhi Xing· 2025-06-25 16:59
证券代码:301017 证券简称:漱玉平民 公告编号:2025-055 债券代码:123172 债券简称:漱玉转债 漱玉平民大药房连锁股份有限公司 关于持股 5%以上股东、董事、高级管理人员权益变动比例 触及 1%整数倍的提示性公告 公司持股 5%以上股东、董事、高级管理人员秦光霞女士保证向本公司提供的信息内容真实、 准确、完整,没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈 述或者重大遗漏。 特别提示: 减持股份计划导致的变动,不涉及要约收购。 前的 73,440,000 股减少至 72,340,000 股,占公司总股本的比例从 18.25%减少至 17.98%。 数量。 漱玉平民大药房连锁股份有限公司(以下简称"公司")于 2025 年 5 月 27 日披露了 《关于持股 5%以上股东、董事、高级管理人员减持股份预披露的公告》,持股 5%以上股东、 董事、高级管理人员秦光霞女士计划在该公告发布之日起 15 个交易日后的 3 个月内(即 股份不超过 12,070,918 股,占公司总股本(已剔除回购专用账户中股份)的 3%。 近日,公司 ...
益丰药房: 中信证券股份有限公司关于益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券2025年第一次临时受托管理事务报告
Zheng Quan Zhi Xing· 2025-06-18 09:27
债券简称:益丰转债 债券代码:113682 中信证券股份有限公司关于 益丰大药房连锁股份有限公司 向不特定对象发行可转换公司债券 发行人 益丰大药房连锁股份有限公司 Yifeng Pharmacy Chain Co., Ltd. (湖南省常德市武陵区白马湖街道富强社区人民路 2638 号) 债券受托管理人 中信证券股份有限公司 (广东省深圳市福田区中心三路 8 号卓越时代广场(二期)北座) 重要声明 本报告依据《可转换公司债券管理办法》《公司债券发行与交易管理办法》 (以下简称《管理办法》)、《公司债券受托管理人执业行为准则》(以下简称 《执业行为准则》)等相关规定及其它相关信息披露文件、益丰大药房连锁股份 有限公司(以下简称"益丰药房","发行人"或"公司")出具的相关文件以 及提供的相关资料或第三方中介机构出具的专业意见等,由本期公司债券受托管 理人中信证券股份有限公司(以下简称"中信证券")编制。 本报告不构成对投资者进行或不进行某项行为的推荐意见,投资者应对相关 事宜做出独立判断,而不应将本报告中的任何内容据以作为中信证券所作的承诺 或声明。 第一节 本次可转换公司债券概况 一、发行人名称 中文名称: ...